🏢 官网IRSGMTCodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:00:00(美东 07:00)·⟳ 抓取 19:01:03·⚡ 决策 08-04 19:02:45 +1m42s·84.0 天前
Sagimet Biosciences宣布将参加Canaccord Genuity年度成长会议
这只是公司管理层参加投资者会议的例行IR预告，没有披露临床、监管、融资、合作或商业化新增事实。
📄 原文SGMT↗ 原文
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
FOSTER CITY, Calif. , Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage bioph…
不做 Sagimet Biosciences（SGMT.US）
例行投资者会议参与预告，无明确方向、无业绩或研发增量、无法形成正期望交易，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 low ↗
关键理由
- 这只是公司管理层参加投资者会议的例行IR预告，没有披露临床、监管、融资、合作或商业化新增事实。
- 事件不改变Sagimet Biosciences（SGMT.US）的短期收入、现金流、研发里程碑或估值锚，无法形成同向交易催化。
原文全文
展开原文 · 1,058 字
FOSTER CITY, Calif.
,
Aug. 04, 2026
(GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46
th
Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link
here
).
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit
www.sagimet.com
.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
,
Aug. 04, 2026
(GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46
th
Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link
here
).
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit
www.sagimet.com
.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。